netFormulary NHS
Isle of Wight
Formulary
 Search
 Formulary Chapter 8: Malignant disease and immunosuppression - Full Chapter
Notes:

Chemotherapy drugs are frequently given in combination.

Disease specific protocols are approved at local and network level.

Only approved protocols should be used. All chemotherapy treatment decisions should be made by a consultant grade oncologist or haematologist, with input from the relevant multidisciplinary team. 

 Chemotherapy drugs, including oral therapies must be prescribed, dispensed and administered only by suitably trained staff. 

Paediatric cancer therapies are initiated and prescribed from tertiary cancer centres. The exception is maintenance treatment for some cancers, which is prescribed by designated paediatricians only.

Cancer Drugs Fund (CDF) - Drug List

Chapter Links...
 Details...
08.02.04  Expand sub section  Other immunomodulating drugs
Lenalidomide Black Triangle
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund

Subject to individual patient enrolment in REVLIMID Risk Evaluation and Mitigation Strategy (REMS)  

 
Link  Lenalidomide for the treatment of multiple myeloma in people who have received at least one prior therapy TA171
Link  Lenalidomide for treating myelodysplastic syndromes associated with an isolated deletion 5q cytogenetic abnormality TA322
Link  REVLIMID REMS
Nivolumab (Opdivo®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
Cancer Drugs Fund
 
Link  NICE TA384: Nivolumab for treating advanced (unresectable or metastatic) melanoma
Link  NICE TA400: Nivolumab in combination with ipilimumab for treating advanced melanoma
Link  NICE TA417: Nivolumab for previously treated advanced renal cell carcinoma
Link  NICE TA462 : Nivolumab for treating relapsed or refractory classical Hodgkin lymphoma
Link  NICE TA483: Nivolumab for previously treated squamous non-small-cell lung cancer
Link  NICE TA484: Nivolumab for previously treated non-squamous non-small-cell lung cancer
Link  NICE TA490: Nivolumab for treating squamous cell carcinoma of the head and neck after platinum-based chemotherapy
Olaparib (Lynparza®)
View adult BNF View SPC online
Formulary
Red
High Cost Medicine
 
Link  NICE TA620: Olaparib for maintenance treatment of relapsed platinum-sensitive ovarian, fallopian tube or peritoneal cancer
Osimertinib (Tagrisso)
View adult BNF View SPC online View childrens BNF
Formulary
Red
 
Link  NICE TA416: Osimertinib for treating locally advanced or metastatic EGFR T790M mutation-positive non-small-cell lung cancer
Thalidomide
(haematology)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine

Subject to individual patient enrolment in Thalomid Risk Evaluation and Mitigation Strategy (REMS)  

 
Link  THALOMID REMS
08.02.04  Expand sub section  Interferon Alfa
Interferon Alfa
(IntronA)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
08.02.04  Expand sub section  Interferon beta
Interferon Beta (Rebif®)
View adult BNF View SPC online View childrens BNF
Formulary
Red
High Cost Medicine
 
Link  NICE TA527: Beta interferons and glatiramer acetate for treating multiple sclerosis
08.02.04  Expand sub section  Interferon gamma
08.02.04  Expand sub section  BCG bladder instillation to top
08.02.04  Expand sub section  Canakinumab
08.02.04  Expand sub section  Dimethyl fumarate
08.02.04  Expand sub section  Fingolimod
08.02.04  Expand sub section  Histamine
08.02.04  Expand sub section  Lenalidomide, pomalidomide, and thalidomide to top
08.02.04  Expand sub section  Teriflunomide
 ....
Key
note Notes
Section Title Section Title (top level)
Section Title Section Title (sub level)
First Choice Item First Choice item
Non Formulary Item Non Formulary section
Restricted Drug
Restricted Drug
Unlicensed Drug
Unlicensed
Track Changes
Display tracking information
click to search medicines.org.uk
Link to adult BNF
click to search medicines.org.uk
Link to children's BNF
click to search medicines.org.uk
Link to SPCs
SMC
Scottish Medicines Consortium
Cytotoxic Drug
Cytotoxic Drug
CD
Controlled Drug
High Cost Medicine
High Cost Medicine
Cancer Drugs Fund
Cancer Drugs Fund
NHSE
NHS England
Homecare
Homecare
CCG
CCG

Traffic Light Status Information

Status Description

Green

Drugs that may be initiated, stabilised and maintained by primary, secondary or tertiary care Secondary and tertiary care prescribing may be continued by primary care. [this does not indicate first/second line choice]  

Green Hospital

Items used by the Hospital but would not normally be continued into primary care. Primary care prescribers can change to GREEN first or second.   

Green plus

Initiation of drugs by primary care following written advice from secondary/ tertiary care advice.  

Yellow

Drugs that may be continued in primary care following initiation and stabilisation in secondary/tertiary care  

Amber

Items requiring a shared care agreement. These items should be initiated and stabilised by secondary or tertiary care. The GP should only be asked to take over prescribing through a formal shared care agreement. Secondary care will be expected to continue prescribing until the agreement is made.  

Red

Hospital/ Trust ONLY. These are items the secondary and tertiary care are responsible for prescribing and will need to continue to prescribe for long term maintenance. These items will NOT be prescribed in primary care. But primary care should be informed the patient is receiving these items. This will include NHSE funded items requiring repatriation.  

GP - Black

Items covered by NHSE ‘Should not prescribe in primary care list’ – See CCG policy on Drugs of limited clinical value  

GP - Grey

Grey List: Items covered by NHSE ‘Should not prescribe in primary care list’ that are not to be routinely prescribed but may be suitable in a defined population – See CCG policy on Drugs of limited clinical value  

netFormulary